Industry NewsAvacta successfully generates several highly specific Affimer reagents for COVID-19 antigen rapid test ahead of schedule as part of Cytiva partnership
Industry NewsAvacta’s proprietary TMAC cancer therapy platform demonstrates successful proof-of-concept in pre-clinical study